Skip to content

Abstract A012: Investigating the heterogeneity of different KRAS point mutations on DRP1 activation and its regulation of the TME in pancreatic cancer

Sep 2026 · Cancer Research · 0 citations

TL;DR

This group identified that DRP1 loss in KRAS-mutant PDAC tumor cells alters mitochondrial shape and reduces glycolysis and cell proliferation in murine models and hypothesize that reliance on DRP1 activation in PDAC is KRAS-mutant-specific and shapes the TME to promote survival.

Abstract

Despite research efforts, outcomes for patients with pancreatic ductal adenocarcinoma (PDAC) remain dismal, with a 5-year survival rate of 13%. Our group identified that DRP1 loss in KRAS-mutant PDAC tumor cells alters mitochondrial shape and reduces glycolysis and cell proliferation in murine models. However, how Ras-induced mitochondrial dynamics in human PDAC models impact the PDAC tumor microenvironment (TME) remains unclear. We hypothesize that reliance on DRP1 activation in PDAC is KRAS-mutant-specific and shapes the TME to promote survival. Four human PDAC patient-derived xenograft (PDX) cell lines with KRAS mutations (PDX 395 & 188 KRASG12Rand PDX 366 & 608 KRASG12D) were stably transduced with a lentivirus in which a tetracycline-responsive promoter drives murine Drp1 expression. Next, the cells were transduced with a lentivirus expressing CAS9 and a guide targeting the human DRP1 gene. To maintain physiological levels of murine Drp1 expression, low-dose doxycycline (dox) kept expression comparable to endogenous human DRP1. We developed two in vivo mouse models: an orthotopic PDX model and a splenic injection model of liver metastasis. In both models, the tumor cells are human, and the TME cells are mouse. To test how DRP1 loss affects primary and metastatic tumor growth, we injected DRP1-/- and control cell lines into the pancreas or spleen. Additionally, in vivo splenic injection experiments using the PDX 395 KRASG12R cell lines, with mice on dox water, controlled when DRP1 is lost during tumor growth. Injecting 395 parent cell lines into mice with no, low (0.25mg/mL), or high (0.5mg/mL) dox water will allow for the understanding of whether dox affects tumor growth in the liver. To identify additional mechanisms that may contribute to differences in in vivo growth, possibly depending on the KRAS point mutation, we performed a cytokine Luminex assay followed by confirmation ELISAs. We will test the DRP1-/- cell lines for this dependance in PDX 366 and 608 KRASG12D, compared with PDX 395 and 188 KRASG12R, by measuring activation of NF-κB, AKT, FAS, and G6PD, and enzymes in glycolysis and the MAPK pathway by immunoblot. We will also perform in vitro macrophage engulfment assays on the PDX 395 KRASG12R and 366 KRASG12D sgcontrol and sgDRP1 cell lines on and off dox. The PDX 395 KRASG12R cell line grows differently in both the pancreas and liver when DRP1 is lost compared to the two KRASG12D cell lines. DRP1 may play a role in establishing the PDX 395 cell line in the liver, and its clearance may be DRP1-dependent. Dox treatment of mice with PDX 395 tumors does not affect tumor clearance in the liver. There is an increased trend in IL-6 secretion from the PDX 395 KRASG12R cell line and a significant three- to fivefold increase in PDX 366 KRASG12D upon DRP1 loss compared to controls. These alterations in IL-6 secretion upon DRP1 loss may represent a DRP1-dependent adaptation. In human PDAC cell lines, adaptations that overcome DRP1 targeting and enable metastasis may be KRAS-mutant-specific. Victoria A. Remley, Varna Selvakumar, Nadiya Harris, Sara J. Adair, David F. Kashatus, PhD, Todd W. Bauer, MD. Investigating the heterogeneity of different KRAS point mutations on DRP1 activation and its regulation of the TME in pancreatic cancer [abstract]. In: Proceedings of the AACR Conference on Pancreatic Cancer: New Frontiers in Biology and Therapeutic Development; 2026 Sep 25-28; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(18_Suppl_2):Abstract nr A012.

View source

Similar papers

Sep 2026

Abstract A054: MICAL2 promotes oncogenic Kras -induced pancreatic cancer initiation by regulating RAC1-mediated acinar to ductal metaplasia

Pancreatic ductal adenocarcinoma (PDAC) is a deadly form of pancreatic cancer with the poorest 5-year survival rate among all solid cancers. Therefore, identifying effective therapeutic strategies is crucial for treating this disease. Using a genome-wide screening approach to find novel and targetable factors in huma...

Nirakar Rajbhandari, Deepa Sheik Pran Babu, E. Mose et al. · 0 citations
#gene editing Sep 2026

Abstract B067: Dissection of the in vitro response landscape in PDAC under KRAS inhibition reveals co-occurring conserved and adaptive transcription programs

In vitro perturbation is used to decipher the early transcriptional response programs in patient-derived 2D and 3D cell models of PDAC to KRAS inhibition and identify a robust RNA-based signature with potential utility for pharmacodynamic monitoring and the study of adaptive resistance.

H. Schürmann, J. Asche, S. Liffers et al. · 0 citations
Sep 2026

Abstract B087: Impact of RAS inhibition on T cell maturation in the PDAC microenvironment

It is suggested that pharmacologic and genetic KRAS inhibition differentially remodel the intratumoral T cell compartment, whereas both induce similar T cell changes within the liver premetastatic niche.

Lauren Gerbereux, Rashmi Kumar, E. Lasse-Opsahl et al. · 0 citations
Sep 2026

Abstract A041: KRAS inhibition drives adaptive surfaceome remodeling and reveals ALPP/ALPPL2 as a targetable vulnerability in pancreatic cancer

These studies establish a comprehensive proteomic resource for the PDAC/KRASi research community and identify ALPP/ALPPL2 as a promising cell surface target for combination with KRASi to drive deeper, sustained responses and prevent or forestall KRASi resistance.

Jonathan M. DeLiberty, Fan-Yi Kong, Qi-Jia Yu et al. · 0 citations
Sep 2026

Abstract B099: Tumor progression locus 2 kinase drives pancreatic cancer immune evasion through a MYBL2-CXCL10 signaling axis

Findings identify a previously unrecognized tumor-intrinsic TPL2-MYBL2-CXCL10 signaling axis that promotes immune evasion and targets TPL2-targeted therapies in PDAC, providing strong rationale for clinical development of TPL2-targeted therapies in PDAC.

Hua-Ping Li, Yu-Tong Geng, Hung-Han Huang et al. · 0 citations
Sep 2026

Abstract A032: Elucidating the role of p53 in suppressing pancreatic ductal adenocarcinoma

Pancreatic ductal adenocarcinoma (PDAC) is frequently diagnosed at advanced, metastatic stages, emphasizing the need to study the earliest events in disease progression. The tumor suppressor p53 strongly opposes PDAC development and is mutated in nearly 75% of cases, yet how wild-type p53 functions to delay cancer on...

Jessica L. Mann, Kathryn J. Hanson, Lucie Dequiedt et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.